enGene Therapeutics Inc
enGene Therapeutics Inc. is a clinical-stage biotechnology company based in Montreal, Canada, that specializes in non-viral genetic medicines. It aims to mainstream gene therapy through the delivery of therapeutics to mucosal tissues and other organs, focusing on reducing treatment burden and improving patient outcomes. The company's lead product candidate is detalimogene voraplasmid, a non-viral gene therapy for non-muscle invasive bladder cancer (NMIBC).